jCyte

Executive Summary

jCyte is a clinical-stage biotechnology company developing jCell, a first-in-class retinal progenitor cell therapy for retinitis pigmentosa (RP), a degenerative retinal disease that leads to blindness. RP affects approximately 1 in 4,000 people worldwide, and there are currently no approved treatments that address the underlying loss of photoreceptor cells. jCell is delivered via a single intravitreal injection and is designed to preserve and restore vision by replacing damaged retinal cells. The therapy has demonstrated a favorable safety profile and functional vision improvements in Phase 2 trials, with a Phase 3 pivotal study ongoing. If successful, jCell could become the first approved cell therapy for a retinal degenerative disease, addressing a significant unmet medical need. The company is based in Newport Beach, California, and has raised substantial funding to support its clinical program.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data readout for jCell in retinitis pigmentosa55% success
• Q2 2026Initiation of regulatory discussions (e.g., FDA end-of-Phase 2 meeting)80% success